Table I.
Current COVID-19 vaccines under clinical investigation, adapted from a previous study (74).
| Vaccine Strategy | Developer | Associated Clinical Trials |
|---|---|---|
| ChAdOx1-S (non-replicating virus) | University of Oxford/AstraZeneca | ISRCTN89951424, 2020-001228-32, 2020-001072-15 |
| Adenovirus type 5 (non-replicating virus) | CanSino Biological/Beijing Institute of Biotechnology | ChiCTR2000031781, ChiCTR2000030906 |
| Nanoparticle-encapsulated viral RNA | Moderna/NIAID | NCT04405076, NCT04283461 |
| Inactivated virus | Wuhan Institute of Biological Products/Sinopharm | ChiCTR2000031809 |
| Inactivated virus | Beijing Institute of Biological Products/Sinopharm | ChiCTR2000032459 |
| Inactivated virus | Sinovac | NCT04383574, NCT04352608 |
| Nanoparticle-encapsulated viral glycoprotein | Novavax | NCT04368988 |
| Nanoparticle-encapsulated viral RNA | BioNTech/Fosun Pharma/Pfizer | 2020-001038-36, NCT04368728 |
| Inactivated virus | Institute of Medical Biology/Chinese Academy of Medical Sciences | NCT04412538 |
| DNA plasmid vaccine | Inovio Pharmaceuticals | NCT04336410 |
| Adenovirus (non-replicating virus) | Gamaleya Research Institute | NCT04436471, NCT04437875 |
| Nanoparticle-encapsulated viral RNA | Imperial College London | ISRCTN17072692 |
| Viral RNA | Curevac | n.a. |
COVID-19, coronavirus disease 2019; n.a., not available.